Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | 3 | Y005248 | — |
HCP called to state that the patient received a third dose of PEDVAXHIB at 6 months of age. No symptomatic adverse events were reported.; HCP called to state that the patient received a third dose of PEDVAXHIB at 6 months of age. No symptomatic adverse events were reported.; This spontaneous report was received from a nurse and refers to a 6-month-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 27-Jan-2025, the patient received the third dose of Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB) (lot #Y005248, which upon internal review confirmed to be a valid lot#; expiration date: 17-Sep-2026), at a dose of 0.5 mL (0.5ml/ series) at 6 months of age (Product administered to patient of inappropriate age) for prophylaxis. No symptomatic adverse events were reported (No adverse event). HCP has declined to answer any further questions and has also declined any AE follow-up.